Trial reportJournal of cosmetic dermatology2025
Treating Acne Scars in Fitzpatrick Skin Types I-VI Using a Novel 1550 nm Non-Ablative Resurfacing Laser With Focal Point Technology.
Trial report in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Treating Acne Scars in Fitzpatrick Skin Types I-VI Using a Novel 1550 nm Non-Ablative Resurfacing Laser With Focal Point Technology.Journal of cosmetic dermatology · 2025Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAcne scars have traditionally been treated with non-ablative fractional resurfacing lasers. Traditional 1550 nm lasers can be limited in energy delivery, skin cooling, and safety across all skin types. A new-generation 1550 nm non-ablative resurfacing laser was recently developed, employing conical beams for high energy delivery through Focal Point Technology.
objectiveTo evaluate the utility of a 1550 nm non-ablative resurfacing laser using Focal Point Technology to improve acne scars in Fitzpatrick skin types I-VI. METHODS AND MATERIALS: A prospective, multi-center clinical study investigated this novel resurfacing laser using 1-6 treatments.
resultsForty-seven subjects with Fitzpatrick skin types I-VI were enrolled and treated. Mean age was 40.2 years, and 59.6% were women. Based on GAIS, 78.0% were rated as improved, with none worsening. Two of three blinded reviewers correctly identified photographs for 92.7% of subjects. Significant improvement in blinded ECCA score was observed (85.6 vs. 55.3; p < 0.0001), with 90.2% achieving at least a 15-point improvement. Treatments were well tolerated.
conclusionThis new-generation 1550 nm non-ablative laser using Focal Point Technology with high energy delivery is safe and effective for acne scar treatment in all Fitzpatrick skin types. Its conical beams and cooling system significantly reduce hyperpigmentation risk in darker skin types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.